Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector.
about
Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccineKunjin Virus Replicon Vectors for Human Immunodeficiency Virus Vaccine DevelopmentRabies virus glycoprotein as a carrier for anthrax protective antigenCharacterization of a single-cycle rabies virus-based vaccine vector.Rhabdovirus-based vectors with human immunodeficiency virus type 1 (HIV-1) envelopes display HIV-1-like tropism and target human dendritic cells.Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response.A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodiesSecond-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenicImmunogenicity of cytopathic and noncytopathic viral vectorsImmunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge.Nonsegmented negative-strand viruses as vaccine vectors.Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses.Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infectionsA role for granulocyte-macrophage colony-stimulating factor in the regulation of CD8(+) T cell responses to rabies virus.Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates.HIV-1(89.6) Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in miceFunctional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.PPEY motif within the rabies virus (RV) matrix protein is essential for efficient virion release and RV pathogenicity.Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes.Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein geneRabies virus stimulates nitric oxide production and CXC chemokine ligand 10 expression in macrophages through activation of extracellular signal-regulated kinases 1 and 2.Identification of viral genomic elements responsible for rabies virus neuroinvasiveness.RNA-based viral vectors.Nonstructural protein 3 of bluetongue virus assists virus release by recruiting ESCRT-I protein Tsg101.APRIL:TACI axis is dispensable for the immune response to rabies vaccination.Targeting Vaccine-Induced Extrafollicular Pathway of B Cell Differentiation Improves Rabies Postexposure Prophylaxis.Budding of PPxY-containing rhabdoviruses is not dependent on host proteins TGS101 and VPS4A.Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity.Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity.
P2860
Q27334697-A720531C-6DB3-4AE5-B7CC-EEC74D83AF23Q27477561-5B75F3E4-E44C-4BC6-BE40-8C7C6E9601D5Q28391261-0672AE4A-AE3B-4608-8AAC-31EC384C054BQ33676502-F5E04D1C-9C54-4E9F-BDB2-3A1C3B44268BQ34327387-3BE4416E-EAB3-4565-84E4-C8DA3E80998FQ34334320-29CE825A-52BA-40D3-99B1-17DEAFA860F3Q34338054-DAA2862B-FE47-4240-BF3A-1CB2D09C2D9CQ34461764-D4ED18F6-9E57-4E40-BA93-CEEADC3C762EQ34716855-E9FCC74C-D805-462B-B62B-EAC3363725A4Q35043107-00344D11-A300-4F06-935C-433DFFA4593FQ35139219-BFF7A889-C7C2-4B30-8151-33CCA05E7521Q35275167-71C53271-E25A-4C38-B232-35C04C8BC877Q35557184-93595E12-1703-4EDA-A247-BD2475CBCA1EQ35803316-3728230A-9DBB-4194-BE55-3526ADFC9B2CQ36073443-B77F57CD-C198-4714-8752-A731500559E0Q36156347-33EFA9B0-2118-47C8-AFB0-A5551ADA0D5FQ36474235-F26BFC9D-060C-4174-BC98-30F597DA4F32Q36898934-2685E562-CBB3-45E5-887F-FD0C61E9F294Q37059997-0CA4A91E-CA9E-4BC5-A924-8A832AA7E582Q37068893-3CD16B07-AD33-455C-AE3C-04BDDD25A449Q37348438-2F51D624-CF99-43EF-8DF0-A3C8E7B27EB9Q37621776-0B4A95D1-F7D2-449E-BCD5-487ED29BC8A0Q38266413-E8EEF2CB-3F0D-42E1-A561-DB06400CF688Q39598340-526B18EF-D103-4918-A4B4-64DFD732DF09Q40158110-D5EF44EC-E300-4DFA-B6E1-7000197042FFQ40355293-2DFD19CA-C434-4935-B665-8126DA7333D1Q40539397-3ABC7F64-77FC-44E0-A451-8A4B74D8AADCQ41217724-A742684F-BCD4-4A54-B676-F0736A6E66FEQ43178486-50AA5199-0491-4D93-8659-C1E6F02DFC65
P2860
Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Expression and immunogenicity ...... bdovirus-based vaccine vector.
@ast
Expression and immunogenicity ...... bdovirus-based vaccine vector.
@en
type
label
Expression and immunogenicity ...... bdovirus-based vaccine vector.
@ast
Expression and immunogenicity ...... bdovirus-based vaccine vector.
@en
prefLabel
Expression and immunogenicity ...... bdovirus-based vaccine vector.
@ast
Expression and immunogenicity ...... bdovirus-based vaccine vector.
@en
P2093
P2860
P1433
P1476
Expression and immunogenicity ...... bdovirus-based vaccine vector.
@en
P2093
J M Orenstein
J P McGettigan
M J Schnell
R J Pomerantz
P2860
P304
P356
10.1128/JVI.75.18.8724-8732.2001
P577
2001-09-01T00:00:00Z